UC Irvine opens clinical trial of novel treatment for brain cancer

October 10, 2012

UC Irvine doctors are enrolling patients with the deadly brain tumor glioblastoma multiforme in a clinical trial of a vaccine that may prevent the cancer's return or spread after surgery.

"Our goal is to train the immune system to recognize and attack the cancer," said Dr. Daniela Bota, neuro-oncologist and co-director of UC Irvine's Comprehensive Brain Tumor Program. She will lead the Phase II trial at UC Irvine of DCVax, which was associated with increased survival in a previous study.

The vaccine is prepared in a lab and combines protein antigens extracted from the patient's tumor with some of his or her . These grow into dendritic cells that, when injected back into the patient, target the and prompt the immune system's T cells to identify and attack remaining .

"Cancer cells are like crabgrass: Once they take root, they're hard to eradicate, even after brain surgery," Bota said. The current treatment for patients with glioblastoma multiforme involves surgery to remove as much of the tumor as possible, followed by radiation and chemotherapy.

"The standard of care prolongs survival, but it does not fully destroy the cancer," Bota said. She believes the vaccine can help eliminate remaining and further extend patients' lives. Only 10 percent of the 12,000 to 14,000 people annually found to have glioblastoma multiforme survive five years.

Patients 18 to 70 newly diagnosed with this brain tumor (also called grade IV astrocytoma) may be eligible to enroll in the trial. For more information, call UC Irvine toll-free at 877-UCSTUDY (877-827-8839) or email ucstudy@uci.edu. Please refer to protocol UCI-08-16.

Explore further: Novel brain tumor vaccine acts like bloodhound to locate cancer cells

More information: Additional information also is available at clinicaltrials.gov/show/NCT00045968

Related Stories

Novel brain tumor vaccine acts like bloodhound to locate cancer cells

January 5, 2012
A national clinical trial testing the efficacy of a novel brain tumor vaccine has begun at Wake Forest Baptist Medical Center, the only facility in the Southeast to participate.

Lifting the fog: Finding by neuro-oncologist could help eliminate 'chemo brain'

September 29, 2011
After receiving her medical degree in her homeland of Romania, Dr. Daniela Bota came to the U.S. to earn a doctorate in molecular biology to better understand why people develop neurodegenerative diseases such as Alzheimer's.

Researchers study vaccine as potential weapon against aggressive brain tumors

July 24, 2012
Researchers at Northwestern Brain Tumor Institute (NBTI) are seeking to understand if a vaccine made from a patient's own blood cells may slow the growth of a type of brain tumor. The trial is studying the vaccine's effect ...

Immunogene therapy combined with standard treatment is safe for patients with brain tumors

August 15, 2011
A clinical trial has shown that a form of gene therapy is safe for treating a deadly form of brain cancer, even when combined with radiation therapy.

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.